January 19, 2022 -- PhenoVista Biosciences announced that it has secured funding from BroadOak Capital Partners. The investment will be used to develop new complex products, such as models of the blood-brain barrier and platforms to better understand neurodegenerative diseases, according to the company.
PhenoVista Biosciences provides customized imaging-based phenotypic assay services. It has developed assays for small and large biotechnology and pharmaceutical companies, as well as government agencies. To date, it has developed over 100 different phenotypic assays.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
